You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,279,035


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,279,035
Title:Nanoparticle complexes of paclitaxel, trastuzumab, and albumin
Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof.
Inventor(s): Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:15/412,536
Patent Claims:1. An antibody-albumin nanoparticle complex comprising albumin, anti-HER2 antibody, and paclitaxel, wherein the antibody is trastuzumab, and wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complex has HER2 binding specificity, wherein the diameter of said complex is between 0.1 .mu.m and 1 .mu.m.

2. The antibody-albumin nanoparticle complex of claim 1, wherein said antibody-albumin nanoparticle complex comprises an alkylating agent.

3. The antibody-albumin nanoparticle complex of claim 2, wherein said alkylating agent is a platinum compound.

4. The antibody-albumin nanoparticle complex of claim 3, wherein said platinum compound is carboplatin.

5. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.9 .mu.m.

6. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and about 0.3 .mu.m.

7. The antibody-albumin nanoparticle complex of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, wherein said antibody-albumin nanoparticle complexes comprise albumin, anti-HER2 antibody, and paclitaxel, wherein the antibody is trastuzumab, and wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have HER2 binding specificity, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.95 .mu.m.

9. The pharmaceutical composition of claim 8, wherein said composition or said antibody-albumin nanoparticle complexes comprise an alkylating agent.

10. The pharmaceutical composition of claim 9, wherein said alkylating agent is a platinum compound.

11. The pharmaceutical composition of claim 10, wherein said platinum compound is carboplatin.

12. The pharmaceutical composition of claim 8, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and about 0.9 .mu.m.

13. The pharmaceutical composition of claim 8, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.3 .mu.m.

14. The pharmaceutical composition of claim 8, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

15. The pharmaceutical composition of claim 8 which is formulated for injection.

16. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof.

17. A method of making an antibody-albumin nanoparticle complex, the method comprising mixing in vitro an aqueous albumin-paclitaxel nanoparticle with an antibody with binding specificity for HER2 under conditions to form the nanoparticle complex, wherein the antibody is trastuzumab, and wherein the diameter of said complex is between 0.1 .mu.m and 1 .mu.m.

Details for Patent 10,279,035

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2032-10-01
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2032-10-01
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2032-10-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.